Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas A Butowski

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
JAMA Oncology|October 31, 2024
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical TrialJann N Sarkaria, Karla V Ballman, Sani H Kizilbash, et al.
Cancer Research|April 13, 2026
IL-6 underlies microenvironment immunosuppression and resistance to therapy in glioblastomaJacob S Young, Nam Woo Cho, Calixto-Hope G Lucas, et al.
Neuro-Oncology Advances|March 7, 2025
Longitudinal profiling of IDH-mutant astrocytomas reveals acquired RAS-MAPK pathway mutations associated with inferior survivalEduardo Rodriguez Almaraz, Geno A Guerra, Nadeem N Al-Adli, et al.
Neuro-Oncology|September 27, 2023
A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomasAtsuro Saijo, Hirokazu Ogino, Nicholas A Butowski, et al.
The Journal of Clinical Investigation|December 9, 2021
Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomasHirokazu Ogino, Jennie W Taylor, Takahide Nejo, et al.
Neuro-Oncology|April 8, 2022
Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomesYalan Zhang, Calixto-Hope G Lucas, Jacob S Young, et al.
Neuro-Oncology Advances|May 19, 2021
The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessmentMaciej M Mrugala, Quinn T Ostrom, Shelley M Pressley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2017
Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive GlioblastomaSara A Byron, Nhan L Tran, Rebecca F Halperin, et al.
Acta Neuropathologica|December 11, 2023
"De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockadeSara Hadad, Rohit Gupta, Nancy Ann Oberheim Bush, et al.
Neuro-Oncology|November 19, 2024
Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responsesCalixto-Hope G Lucas, Nadeem N Al-Adli, Jacob S Young, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
JAMA Oncology|October 31, 2024
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical TrialJann N Sarkaria, Karla V Ballman, Sani H Kizilbash, et al.
Cancer Research|April 13, 2026
IL-6 underlies microenvironment immunosuppression and resistance to therapy in glioblastomaJacob S Young, Nam Woo Cho, Calixto-Hope G Lucas, et al.
Neuro-Oncology Advances|March 7, 2025
Longitudinal profiling of IDH-mutant astrocytomas reveals acquired RAS-MAPK pathway mutations associated with inferior survivalEduardo Rodriguez Almaraz, Geno A Guerra, Nadeem N Al-Adli, et al.
Neuro-Oncology|September 27, 2023
A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomasAtsuro Saijo, Hirokazu Ogino, Nicholas A Butowski, et al.
The Journal of Clinical Investigation|December 9, 2021
Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomasHirokazu Ogino, Jennie W Taylor, Takahide Nejo, et al.
Neuro-Oncology|April 8, 2022
Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomesYalan Zhang, Calixto-Hope G Lucas, Jacob S Young, et al.
Neuro-Oncology Advances|May 19, 2021
The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessmentMaciej M Mrugala, Quinn T Ostrom, Shelley M Pressley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2017
Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive GlioblastomaSara A Byron, Nhan L Tran, Rebecca F Halperin, et al.
Acta Neuropathologica|December 11, 2023
"De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockadeSara Hadad, Rohit Gupta, Nancy Ann Oberheim Bush, et al.
Neuro-Oncology|November 19, 2024
Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responsesCalixto-Hope G Lucas, Nadeem N Al-Adli, Jacob S Young, et al.
Pageof 6